TRAVERE THERAPEUTICS, INC. (TVTX) Gross profit 2016–2025
TRAVERE THERAPEUTICS, INC. (TVTX) annual gross profit history from SEC filings — each fiscal year as reported.
$480.4MFY2025 · since FY2016: $129.0M → $480.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $480.4M | +113.1% |
| FY2024 | $225.4M | +68.5% |
| FY2023 | $133.8M | +27.4% |
| FY2022 | $105.0M | -17.9% |
| FY2021 | $128.0M | -33.4% |
| FY2020 | $192.2M | +13.0% |
| FY2019 | $170.1M | +7.2% |
| FY2018 | $158.7M | +4.9% |
| FY2017 | $151.3M | +17.3% |
| FY2016 | $129.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TVTX financial trends
TVTX RevenueTVTX Net incomeTVTX Net marginTVTX Gross marginTVTX Operating incomeTVTX Operating marginTVTX Operating cash flowTVTX Free cash flowTVTX Capital expendituresTVTX Return on equityTVTX Stock buybacksTVTX Dividends paidTVTX Total assetsTVTX Total liabilitiesTVTX Shareholders’ equityTVTX overview →